Pulmonary hypertension (PH) frequently complicates chronic lung disease and is associated with high morbidity and poor outcomes.Individuals with interstitial lung disease and chronic obstructive pulmonary disease develop PH due to structural changes associated with the destruction of lung parenchyma and vasculature with concurrent vasoconstriction and pulmonary vascular remodeling similar to what is LYCOPENE 10MG observed in idiopathic pulmonary arterial hypertension (PAH).Treatment for PH due to chronic lung disease is largely supportive and therapies specific to PAH have had minimal success in this population with exception of the recently FDA-approved inhaled prostacyclin analogue treprostinil.Given the CUTICLE OIL significant disease burden of PH due to chronic lung diseases and its associated mortality, a great need exists for improved understanding of molecular mechanisms leading to vascular remodeling in this population.
This review will discuss the current understanding of pathophysiology and emerging therapeutic targets and potential pharmaceuticals.